UnitedHealth Q1 '26 Earnings: Wall Street Is in Love Again

Key Takeaways

• Revenue reached $111.7 billion, up from $109.6 billion a year earlier
• Adjusted EPS $7.23 beat consensus $6.57, widest beat since 2021
• Guidance lifted to over $18.25 per share, up $0.50
• Lost 965k Medicare Advantage and 220k Medicaid members this quarter
• Intercompany eliminations rose to $39.5 billion, 256% increase decade‑long

Pulse Analysis

UnitedHealth’s Q1 2026 results highlight a rare earnings surge for the nation’s largest health insurer. Revenue topped $111.7 billion, and adjusted EPS of $7.23 comfortably outpaced analyst forecasts, prompting the stock to rally nearly 9%. The company’s guidance lift to more than $18.25 per share signals confidence in its margin‑recovery playbook, which hinges on tighter cost control, higher pricing, and strategic use of its Optum platform. Investors have rewarded this outlook, but the underlying drivers raise broader industry concerns.

A key component of the margin improvement is the deliberate reduction of high‑cost government‑insured members. UnitedHealth shed almost one million Medicare Advantage enrollees and over two hundred thousand Medicaid members in the quarter, driving the medical loss ratio down to 83.9%—below analyst expectations. While this boosts profitability, it leaves vulnerable seniors and low‑income families scrambling for alternative coverage. The move also dovetails with state eligibility tightening and upcoming work‑requirement reforms that could further erode Medicaid rolls, amplifying the policy debate around insurer‑driven disenrollment.

Beyond enrollment tactics, UnitedHealth is accelerating its digital transformation. A $1.5 billion AI investment powers tools like the Avery chatbot, real‑time prior‑authorization processing, and the Optum Real claims platform, aiming for a 2:1 return within 12‑18 months. Simultaneously, intercompany eliminations surged to $39.5 billion, reflecting the growing internal flow of premiums to owned provider networks—a structure under heightened regulatory scrutiny. As the company balances AI‑driven efficiency with mounting antitrust and DOJ investigations, its ability to sustain earnings growth without compromising patient access will be a focal point for investors and policymakers alike.